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Vascular calcification in the uremic patient: A cardiovascular have supported the association between VC and cardiac
risk? changes in these patients [2].
Background. Several factors suggest that the presence of Alterations in the calcium-phosphate metabolism andvascular calcification (VC) is associated with a high risk of
the treatment of these abnormalities contribute to thecardiac events in uremic patients. The aim of this study was
development of VC in ESRD patients. VC may be oneto analyze the influence of VC on cardiac morbidity and mortal-
ity in our hemodialysis (HD) patients. of the mechanisms by which hyperphosphatemia and
Methods. We studied 79 patients on HD: 43 males, mean elevated Ca x P product influences cardiac mortality in
age 48  15 years old, mean time on HD 83  63 months. this population [7–10].The presence of VC was evaluated by radiologic series. Other
VC induces stiffening of the vessel wall and reducescardiovascular risk factors analyzed were arterial hypertension,
vascular compliance, which has found to be predictivediabetes mellitus, obesity, cigarette smoking, anemia, and dys-
lipidemia. All patients underwent M-mode, two-dimensional, of cardiovascular mortality in these patients [2, 11].
Doppler echocardiography. Patients were followed for two VC in the media of medium- and small-sized vessels in
years. During this time, clinical information collected included
ESRD patients is very marked and may displace intimae,predialysis blood pressure, incidence of ischemic heart disease,
causing luminal narrowing. This may also be applicableepisodes of congestive heart failure, and mortality due to car-
diovascular event. to coronary arteries contributing to cardiovascular com-
Results. VC was observed in 55.7% of patients. Left ventric- plications [12].
ular hypertrophy, diastolic dysfunction, and cardiac valve calci- Finally, soft tissue calcification also includes myocar-
fication were significantly associated with VC. Ischemic heart
dium and cardiac valve calcification, with important con-disease (71.4% vs. 28.6%) and episodes of cardiac failure (0.41
sequences in the cardiac function [5, 13, 14].vs. 0.18 per year; P  0.05) appeared more frequently in the
patient group with VC. VC was present in 80.6% of patients We undertook this prospective study to analyze the
who developed episodes of heart failure. Eight patients died influence of VC on cardiac morbidity and mortality in
from cardiac disease; each of them had VC. our HD patients.Conclusion. The presence of VC can help to identify those
HD patients with a higher cardiovascular risk.
METHODS
We included 79 patients, 43 males and 36 females,End-stage renal disease (ESRD) patients have a sub-
with a mean age of 48  15 years old and mean time onstantially greater risk of cardiovascular death than the
hemodialysis of 83  62 months.population with normal kidney function [1]. In the last
Cardiovascular risk factors analyzed were arterial hy-decade vascular calcification has emerged as a process
pertension (54 patients, 68%), diabetes mellitus (8 pa-with important clinical consequences, and the presence
tients, 10%), obesity (17 patients, 21.5%), and cigaretteof coronary artery calcification has been clearly defined
smoking (25 patients, 31.6%). Other factors assessedas a risk factor for cardiovascular morbidity and mortal-
were hematocrit, serum cholesterol, triglycerides, total/ity [2, 3].
HDL-cholesterol, and lipoprotein(a).Diffuse media calcification of arterial vessels with no
VC was studied by radiograph series that included therelation to atheromatosis is very prevalent in ESRD,
thorax, abdomen, pelvis, and the extremities. VC waseven in young patients [4–6]. Recently, clinical studies
diagnosed when they were found in any of the examined
areas.
Key words: cardiovascular disease, end-stage renal disease. Echocardiography was performed using M-mode
two-dimensional, Doppler color ultrasonography. The 2003 by the International Society of Nephrology
S-119
Salgueira et al: Vascular calcification: Cardiovascular risk?S-120
Table 2. Echocardiographic parametersTable 1. Cardiovascular risk factors
Vascular VC No VC P value
calcification (VC) No VC P value
PWT cm 1.39 (0.4) 1.21 (0.3) 0.05
IVST cm 1.35 (0.4) 1.23 (0.3) 0.05Hypertension 54 patients 30 24 NS
Diabetes 8 patients 7 1 0.05 LVM g/m2 218 (93) 178 (57) 0.05
EF % 70 (6) 72 (5) NSObesity 17 patients 9 8 NS
Smoking 25 patients 11 14 NS PAMV m/s 0.96 (0.4) 0.74 (0.2) 0.05
PEMV m/s 0.75 (0.4) 0.85 (0.5) NSHematocrit % 31 (4) 32 (2) NS
Serum cholesterol mg/dL 257 (75) 182 (64) NS E/A ratio 0.71 (0.2) 1.1 (0.5) 0.05
IVRT m/s 144 (32) 144 (40) NSSerum triglicerides mg/dL 175 (93) 214 (144) 0.05
Lipoprotein (a) mg/dL 51 (44) 22 (9) NS Mitral valve calcification % 82.8 17.2 0.001
Aortic valve calcification % 84.6 15.4 0.001
Diastolic dysfunction % 70.2 29.8 0.001
Abbreviations can be found in the text.
same experienced cardiologist always carried out the
technique in a midweek interdialysis day. Left ventricu- Table 3. Clinical outcome and VC
lar (LV) dimensions were presented according to recom-
VC No VC
mendations of the American Society of Echocardiogra- 44 patients 35 patients P value
phy. The following parameters were assessed: posterior Ischemic disease 21 patients 15 6 0.07
wall thickness (PWT); interventricular septal thickness Heart failure 31 patients 25 6 0.01
Survivors 65 patients 35 30 NS(IVST); LV mass (LVM) calculated by the Penn conven-
Cardiac death 8 patients 8 0 0.05tion formula and indexed to body surface area; ejection
fraction (EF); peak early and peak atrial mitral velocities
(PEMV, PAMV); E/A ratio of transmitral velocities;
Clinical outcomeisovolumetric relaxation time (IVRT); and presence of
calcification in cardiac valves. Predialysis arterial pressure did not differ in both
groups of patients: 140/77 in the VC group versus 134/73.Patients were prospectively followed over two years.
Clinical variables that appearing during this follow-up Twenty-one of the 79 patients (26.6%) developed isch-
emic heart disease during the follow-up period (Tableperiod and were considered in the study included isch-
emic heart disease, the occurrence of myocardial infarction, 3). Most of these patients (15) belonged to the group
with VC.and angina pectoris (intradialysis thoracic pain was not
included). Episodes of heart failure were diagnosed by Thirty-one patients (39%) presented with at least one
episode of congestive heart failure during the two yearsthe presence of recurrent or persistent dyspnea associated
with two of the following things: raised jugular venous of follow-up. These episodes occurred with a significantly
higher frequency in the group of patients with VC (25pressure, bibasilar crackles, pulmonary venous hyperten-
sion, or interstitial edema on chest radiograph. Predialysis patients, 80.6%) (Table 3). The number of episodes per
year was also higher in VC patients (0.41 vs. 0.18).arterial pressure and survival were also considered.
Fourteen patients died from different causes, and
Statistical analysis eight, all of them presenting with VC, died from cardio-
vascular disease. The proportion of deaths attributed toBaseline characteristics were described using median 
interquartile range. Nonparametric statistical tests were cardiac causes was 57%.
used to compare quantitative variables, while Chi-square
test was used for qualitative variables. A P value less
DISCUSSION
than 0.05 indicated statistical significance.
We found a prevalence of VC greater than 50% in our
ESRD patients undergoing regular HD. This prevalence
RESULTS would most likely have been even higher if new and
more sensitive radiologic techniques, such as electron-Vascular calcification was observed in 44 of the 79
patients (55.7%). Table 1 shows the different cardiovas- beam CT, had been used [9]. The presence of VC was
associated with echocardiographic abnormalities. Acular risk factors of the patients grouped according to
the presence of VC. higher degree of LV hypertrophy and more evident alter-
ations in ventricular filling occurred in patients with VC.Patients with VC showed significant differences in
PWT, IVST, and LVM. The presence of VC was associ- Guerin et al [2] observed a significant decrease in stroke
volume and E/A ratio of transmitral velocities in ESRDated with diastolic dysfunction, higher PAMV, and a lower
E/A ratio (pattern of abnormal LV relaxation) (Table 2). subjects with VC. In the same study, VC was associated
with increased stiffening of large arteries. The contribu-VC appeared statistically associated with mitral and
aortic valve calcification. tion of functional and structural changes in the large
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arteries to the genesis of LV hypertrophy has been pre- more episodes of heart failure and ischemic heart dis-
ease. Vascular calcification should be considered aviously documented [15].
The association of VC and cardiac valve calcification marker of cardiovascular risk in hemodialysis patients.
More studies are necessary to learn how to avoid VC,has been frequently observed [4, 5, 13, 16]. The mecha-
nisms responsible for VC in ESRD patients remain un- or how to modify its evolution and complications.
certain. It is possible, however, that alterations in mineral
Reprint requests to Mercedes Salgueira, Servicio de Nefrologı´a,
metabolism play an important role in its development. Virgen Macarena Hospital Universitario, Avda Dr Fedriani 3, 41071-
Sevilla, Spain.[2, 3, 5, 8, 10, 13].
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